Skip to main content
This R&D Website is for US Healthcare Professionals Only

Working Together

By joining with research partners, healthcare and clinical experts, industry peers, patients and patient advocacy groups, and by leveraging our own expertise, our goal is to discover and develop oncology therapies that can potentially make a transformational improvement in cancer treatment. Through progressive science and research, we aim to shape the way cancer is treated.

We are committed to combining the best talent, thinking and resources to foster innovation on behalf of people affected by cancer. That's why our internal research efforts are balanced with external collaborations across the highest levels of industry, academia and government.

Joining Forces to Accelerate Our Oncology Portfolio

Pharmacyclics is an AbbVie company focused on developing and commercializing innovative small-molecule therapies for the treatment of certain cancers and immune-mediated diseases. Pharmacyclics and its partner Janssen Biotech, developed and commercialize IMBRUVICA® (ibrutinib), a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). AbbVie's acquisition of Pharmacyclics is a strategically compelling opportunity that enables us to build a strong leadership position in hematological oncology, where there is significant unmet need.

Partnering with MD Anderson to Advance Immunotherapy

AbbVie's recent collaboration with the immunotherapy platform at the University of Texas MD Anderson Cancer Center will empower us to find new ways to unleash the immune system's potential to fight cancer.

Pairing MD Anderson's cutting-edge preclinical, translational and clinical capabilities with AbbVie's innovative discovery and development programs accelerates our ability to deliver new therapies that can help transform the lives of people affected by cancer.

Facilitating Deeper Collaboration in the Oncology Community

We recognize the value of every voice and mind in the oncology community. We hope that sharing our knowledge and science with the larger professional oncology community will encourage curiosity and healthy dialogue, the outcome of which may lead to greater opportunities to help address areas of unmet needs on behalf of people affected by cancer.

Strategic Collaborations

AbbVie is dedicated to tackling the toughest challenges in oncology, through our own research and through strategic collaborations with external organizations, in order to advance our science.

These partnerships are developed to pursue two critical goals: discovering and developing new medicines and improving patient outcomes. Our partners share this patient-focused commitment to help address areas of unmet needs in oncology.

We are proud to work with a range of organizations - including the select list below - to make a remarkable impact on the lives of people affected by cancer around the world:

Visit to view our full list of collaboration partners.

Unless otherwise specified, all product names appearing on this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress on this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.